Gilead Sciences, Inc. (GILD) vs Johnson & Johnson (JNJ)
- Gilead Sciences, Inc. GILD 156.19 −0.75%
- Johnson & Johnson JNJ 255.55 +0.90%
Gilead Sciences, Inc. and Johnson & Johnson are both Drug Manufacturers General companies. Johnson & Johnson is the larger, with a market value of $610.4B against $195.1B — 3.1× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Johnson & Johnson trades at 29.6×. Johnson & Johnson grew revenue faster over the last twelve months: 7.80% against 5.52%. Johnson & Johnson has the higher net margin (16.2% vs −10.6%) and the higher return on invested capital (0.00% vs −4.48%). Both pay a dividend; Gilead Sciences, Inc. yields more (2.08% vs 2.07%). Across the 22 metrics below, Johnson & Johnson leads on 13 and Gilead Sciences, Inc. on 9.
Valuation
Profitability
| Metric | GILD | JNJ | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.59% | 67.56% | 72.77% |
| Operating margin | (8.20%) | 19.29% | 18.77% |
| Net margin | (10.64%) | 16.20% | 8.27% |
| Free cash flow margin | 42.50% | 0.00% | 17.18% |
| Return on equity | (20.68%) | 0.00% | 5.87% |
| Return on assets | (6.17%) | 0.00% | 2.57% |
| Return on invested capital | (4.48%) | 0.00% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack